Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
Compass Therapeutics, a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City on June 5-6, 2024.
The chat is scheduled for June 5 at 1:00-1:25 PM ET and will be webcast live. The presentation will be archived for 90 days on the company's events page.
- Participation in a major conference like Jefferies Global Healthcare Conference enhances visibility and investor interest.
- Webcast of the fireside chat provides accessible information to a broader audience, including potential investors.
- Archiving the presentation for 90 days allows for extended reach and engagement.
- No new clinical data or significant business updates were announced, which might disappoint investors expecting substantial news.
- Participation in a conference has immediate financial impact on stock performance.
- The press release is short on details about ongoing or future clinical trials, leading to uncertainty.
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place in New York City, NY June 5 – 6, 2024.
Fireside Chat details
Date: Wednesday, June 5, 2024
Time: 1:00 – 1:25 PM ET
Webcast Link: https://wsw.com/jefferieswebcast/cmpx/
Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’ Events page.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Senior Communications Manager
media@compasstherapeutics.com
617-500-8099
FAQ
When is Compass Therapeutics participating in the Jefferies Global Healthcare Conference?
What time is Compass Therapeutics' fireside chat at the Jefferies Global Healthcare Conference?
Where can I watch the Compass Therapeutics fireside chat at the Jefferies Global Healthcare Conference?
How long will the Compass Therapeutics presentation be available after the Jefferies conference?
